# Ann-Lii Cheng

Source: https://onco.cc/people/ann-lii-cheng/  
OnCo record `ann-lii-cheng` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.

## Summary

Ann-Lii Cheng led the Asia-Pacific trial that confirmed sorafenib's benefit in hepatitis B-driven hepatocellular carcinoma and was co-principal investigator of IMbrave150, which established atezolizumab plus bevacizumab as first-line therapy. He has led or co-led most major HCC systemic therapy trials in Asia, including REFLECT (lenvatinib) and the adjuvant IMbrave050 study.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: hcc; immunotherapy; asia
- Role: Distinguished Professor and Director, National Taiwan University Cancer Center
- Specialisms: Hepatocellular carcinoma; Immunotherapy; Asia-Pacific trials; Targeted therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- institutions: [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/)
- trials: [IMbrave050](https://onco.cc/trials/imbrave050/), [IMbrave150](https://onco.cc/trials/imbrave150/), [REFLECT](https://onco.cc/trials/reflect/)
- key papers: [IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer](https://onco.cc/key-papers/paper-imbrave150-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/ann-lii-cheng.json